219 related articles for article (PubMed ID: 24519956)
1. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.
Goc A; Al-Husein B; Katsanevas K; Steinbach A; Lou U; Sabbineni H; DeRemer DL; Somanath PR
Oncotarget; 2014 Feb; 5(3):775-87. PubMed ID: 24519956
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
3. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
4. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
[TBL] [Abstract][Full Text] [Related]
5. Src controls castration recurrence of CWR22 prostate cancer xenografts.
Su B; Gillard B; Gao L; Eng KH; Gelman IH
Cancer Med; 2013 Dec; 2(6):784-92. PubMed ID: 24403252
[TBL] [Abstract][Full Text] [Related]
6. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Rice L; Lepler S; Pampo C; Siemann DW
Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
[TBL] [Abstract][Full Text] [Related]
7. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
9. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
[TBL] [Abstract][Full Text] [Related]
10. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
[TBL] [Abstract][Full Text] [Related]
13. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
Tatarov O; Mitchell TJ; Seywright M; Leung HY; Brunton VG; Edwards J
Clin Cancer Res; 2009 May; 15(10):3540-9. PubMed ID: 19447874
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Trevino JG; Summy JM; Lesslie DP; Parikh NU; Hong DS; Lee FY; Donato NJ; Abbruzzese JL; Baker CH; Gallick GE
Am J Pathol; 2006 Mar; 168(3):962-72. PubMed ID: 16507911
[TBL] [Abstract][Full Text] [Related]
15. Significance of ER-Src axis in hormonal therapy resistance.
Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.
Schütz SV; Schrader AJ; Zengerling F; Genze F; Cronauer MV; Schrader M
PLoS One; 2011; 6(9):e25341. PubMed ID: 21980429
[TBL] [Abstract][Full Text] [Related]
17. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer.
Liao X; Zhang L; Thrasher JB; Du J; Li B
Mol Cancer Ther; 2003 Nov; 2(11):1215-22. PubMed ID: 14617795
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer.
Liao X; Thrasher JB; Holzbeierlein J; Stanley S; Li B
Endocrinology; 2004 Jun; 145(6):2941-9. PubMed ID: 14988390
[TBL] [Abstract][Full Text] [Related]
20. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]